- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Ocala Today
By the People, for the People
AIM ImmunoTech CEO to host Feb. 19 investor webcast
Investors can hear about Ampligen's clinical and regulatory path and the DURIPANC trial with AstraZeneca's Imfinzi
Published on Feb. 12, 2026
Got story updates? Submit your updates here. ›
AIM ImmunoTech Inc. announced that its CEO, Thomas K. Equels, will participate in a Virtual Investor Closing Bell Event on Thursday, February 19, 2026, at 4:00 PM ET. Equels will focus on AIM's clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing DURIPANC clinical trial in collaboration with AstraZeneca combining Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer.
Why it matters
Pancreatic cancer is a lethal and unmet global health problem, so AIM's work on developing Ampligen as a potential treatment option is significant. The DURIPANC trial with AstraZeneca represents a key collaboration that could advance a new combination therapy for this devastating disease.
The details
AIM ImmunoTech is an immuno-pharma company focused on the research and development of its lead product, Ampligen, for the treatment of late-stage pancreatic cancer. Ampligen is a dsRNA and highly selective TLR3 agonist immuno-modulator that has shown broad-spectrum activity in clinical trials. The upcoming webcast will provide investors with an update on Ampligen's clinical and regulatory path, as well as details on the DURIPANC trial which is combining Ampligen with AstraZeneca's Imfinzi.
- The webcast will take place on Thursday, February 19, 2026 at 4:00 PM ET.
The players
Thomas K. Equels
Chief Executive Officer of AIM ImmunoTech Inc.
AIM ImmunoTech Inc.
An immuno-pharma company focused on the research and development of its lead product, Ampligen, for the treatment of late-stage pancreatic cancer.
AstraZeneca
A pharmaceutical company collaborating with AIM ImmunoTech on the DURIPANC clinical trial, which is combining Ampligen with AstraZeneca's Imfinzi (durvalumab) immune checkpoint inhibitor.
What they’re saying
“Equels will focus on AIM's clinical and regulatory strategy for its lead drug Ampligen, with an emphasis on the ongoing DURIPANC clinical trial in collaboration with AstraZeneca combining Ampligen and AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi (durvalumab) in the treatment of metastatic pancreatic cancer.”
— Thomas K. Equels, Chief Executive Officer (stocktitan.net)
What’s next
The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.
The takeaway
This webcast represents an important update from AIM ImmunoTech on its efforts to develop Ampligen as a potential new treatment option for the devastating disease of metastatic pancreatic cancer, including details on its collaboration with AstraZeneca.
